ASEAN and North Asian Point of Care/Rapid Diagnostics Market

ASEAN and North Asian Point of Care/Rapid Diagnostics Market by Product (Glucose Monitoring, COVID, HIV, STDs, HAIs, Influenza, Tropical & Respiratory diseases), Technique (Rapid test, Molecular diagnostics), User (Hospital, Home Care) - Forecast to 2026

Report Code: MD 8010 Nov, 2021, by marketsandmarkets.com

[224 Pages Report] The ASEAN and North Asian Point of Care/Rapid Diagnostics market size is expected to grow from an estimated USD 2.0 billion in 2021 to USD 3.9 billion by 2026, at a CAGR of 13.0%. The growing demand for accurate and early diagnostic methodologies, modernization and expansion of healthcare infrastructure and significant disease prevalence are the major factors that are expected to drive the growth of the ASEAN and North Asian Point of Care/Rapid Diagnostics market during the forecast period. However, dearth of skilled healthcare providers and the high out-of-pocket healthcare expenditure are the key factors hindering the growth of this market.

ASEAN and North Asian Point of Care/Rapid Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on the Global ASEAN and North Asian Point of Care/Rapid Diagnostics market

The current global COVID-19 pandemic has significantly impacted markets across multiple sectors and industries such as healthcare, oil & petroleum, aeronautics & defense, and food & beverage. Majority of these industries are experiencing a period of uncertainty in terms of global economic conditions, the regional impact of the pandemic on businesses, government laws and preventive regulations, demand from end users, and challenges faced in the supply chain and logistics. As a result, key businesses and market players are forced to shift focus from long-term growth strategies to short-term sustainability tactics that have led to changes in business operations such as manufacturing, supplying, and consumer communication in certain sectors of the global economy. The healthcare sector is at the epicenter of this global pandemic challenge and is expected to have major long-term consequences. This is expected to compel countries and key market players to undergo crucial healthcare reforms once the crisis is eventually under control or has faded. The private healthcare sector is facing twice the burden—investing additional manpower, equipment, consumables, and other resources to ensure 100% preparedness for safety in hospitals and the eventual treatment of patients alongside the sharp drop in out-patient footfall, elective surgeries, and international patients. Moreover, hospitals are affected by this pandemic as a clear lack in the number of healthcare professionals is being experienced in developed as well as developing countries. Various regional governments imposed stringent mitigation measures due to the COVID-19 pandemic during 2020-21, including travel restrictions, lockdown measures, and deprioritization of non-essential medical services. Additionally, supply chain disruptions, due to lockdowns and quarantine measures, resulted in the limited availability of raw materials and essential healthcare products in target countries, including merchandise trade.

ASEAN and North Asian Point of Care/Rapid Diagnostics Market Dynamics

Driver: Evolving patient preferences and rapid modernization of healthcare services are poised to augment the PoC diagnostics market growth in target countries during next decade

Rapid rates of urbanization and development within the ASEAN and North Asian countries have boosted the overall healthcare environment. Moreover, approximately half of the SEA population lives in urban areas. The ASEAN region is expected to surpass the EU as the world’s second-largest med-tech market (after the US), and most customers will lie beyond the premium segment. Universal insurance schemes are covering more and more people, which will lead to favorable conditions for growth. In addition, ASEAN and North Asian point of care diagnostics are being adopted due to the growing demand for accurate and early diagnostic methodologies.

Restraints: Dearth of skilled workforce and significant out-of-pocket healthcare expenditure across target countries are dampening the optimal market growth for PoC diagnostics products

High out-of-pocket expenditure could be attributed to the tendency of patients to not follow pathways covered by insurance and self-refer to higher-level hospitals for care. According to the WHO, ~65 million people are pushed into poverty because of health expenditure mainly because of direct out-of-pocket expenditures, which adds to the already high incidence of poverty in Southeast Asia. Indonesia, Vietnam, and the Philippines are implementing universal health coverage plans, but out-of-pocket spending remains high due to low reimbursement for over-the-counter and patented drugs and inadequate insurance coverage of services. Southeast Asia faces challenges such as shortages, unequal distribution, retention, adapting health workers’ education to fit rapidly changing needs, and improving health worker performance. They are a major factor restraining the growth of the ASEAN and North Asian Point of Care/Rapid Diagnostics market in the coming years.

Opportunities: Growth potential offered by emerging markets

Workflow automation and decentralization of diagnostic services offer significant revenue growth opportunities for PoC diagnostic vendors in the region during next decade. Emerging health tech has thrown the spotlight on four areas that set the forces of decentralization in motion. The four areas to watch are Decentralized healthcare at home, Decentralized healthcare at clinics, Insurance providers and HMOs shifting their orientation towards digital solutions, and Major players’ response to decentralization. More than half the labs in developed countries in Asia reported using automation systems, compared to only 28.7% in developing countries. Large labs, defined as those processing over 1,000 samples/day, had a relatively high rate of adoption compared to smaller labs. This suggests that automation of diagnostic workflows is a significant growth opportunity in the ASEAN and North Asian Point of Care/Rapid Diagnostics market.

Infectious Disease Diagnostics are the largest product segment in the ASEAN and North Asian Point of Care/Rapid Diagnostics market

Based on product, the ASEAN and North Asian Point of Care/Rapid Diagnostics market is segmented into Infectious Disease Diagnostics, Glucose Monitoring, Cancer Marker Testing, Cardiometabolic Monitoring, Cholesterol Testing, Coagulation Monitoring, Hematology Testing, Urinalysis, Drugs-of-abuse Testing, Pregnancy & Fertility Testing, Fecal Occult Testing and other PoC Diagnostic products. Infectious diseases are expected to account for the largest share of the ASEAN and North Asian Point of Care/Rapid Diagnostics market in 2021. Infectious disease diagnostics dominates the ASEAN and North Asian Point of Care/Rapid Diagnostics market owing to greater patient population and extensive market availability.

Molecular Diagnostics is estimated to be having the highest demand in the technology segment in the ASEAN and North Asian Point of Care/Rapid Diagnostics market

On the basis of technology, the ASEAN and North Asian Point of Care/Rapid Diagnostics market is segmented into Lateral Flow Assays, Immunoassays, Molecular Diagnostics, Microfluidics, Rapid Testing and Dipsticks. Molecular diagnostic technologies are projected to experience higher demand owing to supportive regulations, techno-commercial advantages, and rising public awareness

South Korea, Hong Kong, and Taiwan are among the top ASEAN countries to dominate the point-of-care diagnostics market.

The high growth in this regional market is majorly attributed to factors such as the growing demand for accurate and early diagnostic methodologies.

ASEAN and North Asian Point of Care/Rapid Diagnostics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

The major players in the ASEAN and North Asian Point of Care/Rapid Diagnostics market are Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Abbott Laboratories (US), Danaher Corporation (US), Becton, Dickinson and Company (US), Sysmex (Japan), Cardinal Health (US), Quidel (US), GE Healthcare (US) EKF Diagnostics (UK), bioMérieux SA (France), Accubiotech (China), PTS Diagnostics (US), Chembio Diagnostics (US) Trinity Biotech (Ireland), Johnson and Johnson(US), Sekisui Diagnostics (US), Nova Biomedical (US), Thermo Fisher Scientific (US), Ortho Clinical Diagnostics (US) and Bio-Techne (US).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market Size available for years

2019–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD)

Segments covered

Product, Technology, End User, and Country

Geographies covered

South Korea, Hong Kong, Indonesia, Thailand, Philippines, Vietnam, Malaysia, Singapore, Taiwan, Myanmar, Laos, and Cambodia

Companies covered

Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Abbott Laboratories (US), Danaher Corporation (US), Becton, Dickinson and Company (US), Sysmex (Japan), Cardinal Health (US), Quidel (US), GE Healthcare (US) EKF Diagnostics (UK), bioMérieux SA (France), Accubiotech (China), PTS Diagnostics (US), Chembio Diagnostics (US) Trinity Biotech (Ireland), Johnson and Johnson(US), Sekisui Diagnostics (US), Nova Biomedical (US), Thermo Fisher Scientific (US), Ortho Clinical Diagnostics (US) and Bio-Techne (US).

This research report categorizes the ASEAN and North Asian Point of Care/Rapid Diagnostics market based on product, technology, end user, and country.

Based on the Product:

  • Infectious Disease Diagnostics
    • Influenza Testing
    • Respiratory Infection Testing
    • Tropical Disease Testing
    • HIV Testing
    • STD Testing
    • Hepatitis C Testing
    • HAI Testing
    • COVID Testing
    • Other Infectious Disease Testing*
  • Glucose Monitoring
  • Cancer Marker Testing
  • Cardiometabolic Monitoring
  • Cholesterol Testing
  • Coagulation Monitoring
  • Hematology Testing
  • Urinalysis
  • Drugs-of-abuse Testing
  • Pregnancy & Fertility Testing
  • Fecal Occult Testing
  • Other POC Diagnostic Products**

Other infectious disease testing products include hepatitis A and B testing products, liver testing products, and Ebola testing products

** Other point-of-care products include multi-assay testing, disease-resistant bacteria testing, vitamin assay testing, and other testing products

Based on Technology:

  • Lateral Flow Assays
  • Immunoassays
  • Molecular Diagnostics
  • Microfluidics
  • Rapid Testing
  • Dipsticks

Based on End User:

  • Hospitals & Critical Care Centers
  • Outpatient & Ambulatory Care Centers
  • Home Care Settings
  • Other End Users

Based on the Country:

  • South Korea
  • Hong Kong
  • Indonesia
  • Thailand
  • Philippines
  • Vietnam
  • Malaysia
  • Singapore
  • Taiwan
  • Myanmar
  • Laos and Cambodia

Recent Developments

  • In 2021 Roche partnered with Sysmex (Japan). The Renewed partnership with Sysmex is to deliver hematology testing solutions.
  • In 2021, Siemens acquired Fast Track Diagnostics (Luxembourg). This acquisition is to integrate Fast Track’s offerings into Siemens’ portfolio, thus expanding its molecular diagnostics business.

Frequently Asked Questions (FAQs):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION
    1.1 OBJECTIVES OF THE STUDY 
    1.2 MARKET DEFINITION 
           1.2.1 MARKET SCOPE
           1.2.2 GEOGRAPHIC SCOPE
           1.2.3 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY USED FOR THE STUDY 
    1.4 KEY STAKEHOLDERS 

2 RESEARCH METHODOLOGY 
    2.1 RESEARCH DATA 
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
    2.2 MARKET SIZE ESTIMATION METHODOLOGY 
    2.3 MARKET DATA VALIDATION AND TRIANGULATION
    2.4 RESEARCH ASSUMPTIONS 
    2.5 RESEARCH LIMITATIONS 

3 EXECUTIVE SUMMARY 
    FIGURE1: ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY
    FIGURE2: ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER

4 MARKET OVERVIEW 
    4.1 ASIA: MARKET DYNAMICS 
           4.1.1 MAJOR DRIVERS
           4.1.2 KEY RESTRAINTS
           4.1.3 KEY GROWTH OPPORTUNITIES
           4.1.4 INDUSTRY-SPECIFIC CHALLENGES
    4.2 ASIA: PRICING TREND ANALYSIS FOR TARGET PRODUCT SEGMENTS (IN TERMS OF USD, AS OF 2020/21) 
           4.2.1 ASEAN
           4.2.2 SOUTH KOREA
           4.2.3 GREATER CHINA
           4.2.4 OTHER ASIAN COUNTRIES
    4.3 ASIA: COVID-SPECIFIC INDUSTRY TRENDS
    4.4 ASIA: REGULATORY LANDSCAPE (AS OF 2020/21)

5 POINT OF CARE DIAGNOSTICS MARKET VALUE DATA, BY PRODUCT TYPE   (USD MILLION; 2019 — 2026)* 
           TABLE 1 ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION) 
           TABLE 2 ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION) 
    5.1 INFECTIOUS DISEASE DIAGNOSTICS
           5.1.1 COVID TESTING
           5.1.2 HIV TESTING
           5.1.3 RESPIRATORY INFECTION TESTING
           5.1.4 INFLUENZA TESTING
           5.1.5 TROPICAL DISEASE TESTING
           5.1.6 STD TESTING
           5.1.7 HEPATITIS C TESTING
           5.1.8 HOSPITAL ACQUIRED INFECTION TESTING
           5.1.9 OTHER INFECTIOUS DISEASE TESTING
    5.2 GLUCOSE MONITORING
           5.2.1 GLUCOSE TEST STRIPS
           5.2.2 GLUCOMETERS
           5.2.3 LANCETS
    5.3 CARDIOMETABOLIC MONITORING
           5.3.1 CARDIAC MARKER TESTING
           5.3.2 HBA1C TESTING
           5.3.3 BLOOD GAS AND ELECTROLYTE TESTING
    5.4 COAGULATION MONITORING
    5.5 PREGNANCY AND FERTILITY TESTING 
    5.6 URINALYSIS
    5.7 CANCER MARKER TESTING
    5.8 CHOLESTEROL TESTING
    5.9 HEMATOLOGY TESTING
    5.10 FECAL OCCULT TESTING
    5.11 DRUG OF ABUSE TESTING
    5.12 OTHER POC PRODUCTS

6 POINT OF CARE DIAGNOSTICS MARKET VALUE DATA, BY TECHNOLOGY    (USD MILLION; 2019 — 2026)*
    TABLE 3 ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 
    6.1 RAPID TESTS
    6.2 IMMUNOASSAY
    6.3 LATERAL FLOW ASSAY
    6.4 MICROFLUIDICS
    6.5 MOLECULAR DIAGNOSTICS
    6.6 DIPSTICKS

7 POINT OF CARE DIAGNOSTICS MARKET VALUE DATA, BY END USER  (USD MILLION; 2019 — 2026)*
           TABLE 4 ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 
    7.1 HOSPITALS AND CRITICAL CARE CENTERS
    7.2 OUTPATIENT AND AMBULATORY CARE CENTERS
    7.3 HOME CARE
    7.4 OTHER END USERS 

8 POINT OF CARE DIAGNOSTICS MARKET VALUE DATA, BY COUNTRY  (USD MILLION; 2019 — 2026)*
    8.1 INDONESIA
           TABLE 5 INDONESIA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD   MILLION) 
           TABLE 6 INDONESIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION) 
           TABLE 7 INDONESIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 
           TABLE 8 INDONESIA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 
    8.2 LAOS AND CAMBODIA 
           TABLE 9 LAOS AND CAMBODIA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD   MILLION) 
           TABLE 10 LAOS AND CAMBODIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION) 
           TABLE 11 LAOS AND CAMBODIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 
           TABLE 12 LAOS AND CAMBODIA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 
    8.3 MALAYSIA
           TABLE 13 MALAYSIA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD   MILLION) 
           TABLE 14 MALAYSIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION) 
           TABLE 15 MALAYSIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 
           TABLE 16 MALAYSIA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 
    8.4 MYANMAR
           TABLE 17 MYANMAR POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD   MILLION) 
           TABLE 18 MYANMAR POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION) 
           TABLE 19 MYANMAR POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 
           TABLE 20 MYANMAR POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 
    8.5 PHILIPPINES
           TABLE 21 PHILIPPINES POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD   MILLION) 
           TABLE 22 PHILIPPINES POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION) 
           TABLE 23 PHILIPPINES POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 
           TABLE 24 PHILIPPINES POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 
    8.6 SINGAPORE
           TABLE 25 SINGAPORE POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD   MILLION) 
           TABLE 26 SINGAPORE POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION) 
           TABLE 27 SINGAPORE POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 
           TABLE 28 SINGAPORE POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 
    8.7 THAILAND
           TABLE 29 THAILAND POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD   MILLION) 
           TABLE 30 THAILAND POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION) 
           TABLE 31 THAILAND POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD 
           TABLE 32 THAILAND POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 
    8.8 VIETNAM
           TABLE 33 VIETNAM POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD   MILLION) 
           TABLE 34 VIETNAM POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION) 
           TABLE 35 VIETNAM POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 
           TABLE 36 VIETNAM POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 
    8.9 SOUTH KOREA
           TABLE 37 SOUTH KOREA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD   MILLION) 
           TABLE 38 SOUTH KOREA POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION) 
           TABLE 39 SOUTH KOREA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 
           TABLE 40 SOUTH KOREA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 
    8.10 HONG KONG
           TABLE 41 HONG KONG KOREA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD   MILLION) 
           TABLE 42 HONG KONG POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION) 
           TABLE 43 HONG KONG POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 
           TABLE 44 HONG KONG POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 
    8.11 TAIWAN
           TABLE 45 TAIWAN POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD   MILLION) 
           TABLE 46 TAIWAN POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION) 
           TABLE 47 TAIWAN POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 
           TABLE 48 TAIWAN POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 

9  COMPETITIVE LANDSCAPE 
    9.1 OVERVIEW 
    9.2 ASEAN: POINT OF CARE DIAGNOSTICS MARKET SHARE ANALYSIS BY TOP 5 VENDORS (IN TERMS OF %REVENUE, IN 2020) 
    9.3 ASEAN: COMPETITIVE SCENARIO (2018-2021)
           9.3.1 PRODUCT LAUNCHES
           9.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
           9.3.3 GEOGRAPHIC EXPANSIONS
           9.3.4 ACQUISTIONS
    9.4 ASEAN: COMPETITIVE LEADERSHIP MAPPING FOR MAJOR PLAYERS (AS OF 2021)
           9.4.1 PARTICIPANTS
           9.4.2 EMERGING LEADERS
           9.4.3 PERVASIVE PLAYERS
           9.4.4 STARS

10 COMPANY PROFILES**
(Business overview, product portfolio, industry-specific developments in 2018-2021***) 
     10.1 ABBOTT LABORATORIES
     10.2 ACCUBIOTECH
     10.3 BECTON. DICKINSON AND COMPANY
     10.4 JOHNSON & JOHNSON
     10.5 BIOMERIEUX
     10.6 GE HEALTHCARE
     10.7 ORTHOCLINICAL DIAGNOSTICS
     10.8 BIOTECHNE
     10.9 EKF DIAGNOSTICS
     10.10 SYSMEX
     10.11 ROCHE DIAGNOSTICS
     10.12 SEKISUI DIAGNOSTICS
     10.13 SIEMENS HEALTHINEERS
     10.14 THERMO FISHER SCIENTIFIC
     10.15 TRINITY BIOTECH
     10.16 CHEMBIO
     10.17 CARDINAL HEALTH
     10.18  PTS DIAGNOSTICS
     10.19 QUIDEL
     10.20 INSTRUMENTATION LABORATORY (A WERFEN COMPAN

11 APPENDIX 
           

This study involved four major activities in estimating the current size of the ASEAN and North Asian Point of Care/Rapid Diagnostics market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and market sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were used to estimate the total market size. After that, the market breakdown and data triangulation were done to determine the market size of the segments and sub-segments.

Secondary Research

This research study involved the use of extensive secondary sources, directories, and databases, such as Hoover’s, Bloomberg BusinessWeek, Factiva, and OneSource, to identify and collect information useful for a technical, market-oriented, and commercial study of the ASEAN and North Asian Point of Care/Rapid Diagnostics market. The other secondary sources included intergovernmental organizations, government agencies, annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, manufacturer associations, trade directories, and databases. 

Primary Research

The ASEAN and North Asian Point of Care/Rapid Diagnostics market comprises several stakeholders, such as end-product manufacturers. The demand-side of this market is characterized by its end-users, such as hospitals & clinics, testing labs, e-commerce platforms, among others. The supply-side is characterized by raw material providers, integrators, and others. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

ASEAN and North Asian Point of Care/Rapid Diagnostics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches have been used to estimate and validate the size of the ASEAN and North Asian Point of Care/Rapid Diagnostics market and its dependent submarkets. These methods were also used extensively to determine the extent of various sub-segments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and demand have been identified through extensive secondary research, and their market share has been determined through both primary and secondary research.
  • The industry’s market size, in terms of value, have been determined through primary and secondary research processes.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.  
  • All the possible parameters that affect the market segments covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
  • The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

Data Triangulation

After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and subsegments. To complete the whole market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the end-use industries.

Report Objectives

  • To define, describe, and forecast the ASEAN and North Asian Point of Care/Rapid Diagnostics market based on product, technology, end user and country.
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall ASEAN and North Asian Point of Care/Rapid Diagnostics market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To strategically profile the key global players and comprehensively analyze their market shares and core competencies
  • To track and analyze competitive developments such as product launches, upgrades, and approvals; partnerships, agreements, and collaborations; acquisitions; and expansions in the ASEAN and North Asian Point of Care/Rapid Diagnostics market
  • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes players on various parameters within the broad categories of business and product excellence strategy

ASEAN and North Asian Point of Care/Rapid Diagnostics Market Size, and Share

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the client’s specific needs. The following customization options are available for the ASEAN and North Asian Point of Care/Rapid Diagnostics market report:

Regional Analysis

  • Further breakdown of region or country-specific analysis

Company Information

  • Detailed analyses and profiling of additional market players (up to 5)
COVID-19

Get in-depth analysis of the COVID-19 impact on the ASEAN and North Asian Point of Care/Rapid Diagnostics Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the ASEAN and North Asian Point of Care/Rapid Diagnostics Market

Request For Special Pricing
Report Code
MD 8010
Published ON
Nov, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the ASEAN and North Asian Point of Care/Rapid Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved